FDA Clearance Tracker · P970051-S172
NUCLEUS 24 COCHLEAR IMPLANT SYSTEM
Last checked: Nov 20, 2026Latest source record: Mar 17, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Mar 17, 2020
Approved
Time to decision
889 days
Received Oct 10, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P970051-S172
- Device name
- NUCLEUS 24 COCHLEAR IMPLANT SYSTEM
- Applicant
- Cochlear Americas
- Applicant location
- Lone Tree, CO
- Received
- Oct 10, 2017
- Decided
- Mar 17, 2020
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P970051
Device type
- Device type
- Implant, cochlear (MCM)
- Device class
- Class III
- Specialty
- Otolaryngology (ENT)
FDA's approval statement
As written in FDA's record.
Approval for the IFU for Nucleus 24 Cochlear Implant System: 1) The Nucleus 24 Cochlear Implant System is intended for individuals 18 years of age or older who have bilateral, pre, peri or postlinguistic sensorineural hearing impairment and obtain limited benefit from appropriate binaural hearing aids.2) These individuals typically have moderate to profound hearing loss in the low frequencies and profound (>= 90 dB HL) hearing loss in the mid to high speech frequencies. Limited benefit from amplification is defined by test scores of 50% correct or less in the ear to be implanted (60% or less in the best-aided listening condition) on tape-recorded tests of open set sentence recognition.3) The Nucleus 24 cochlear implant system is intended for use in children 9 to 24 months of age who have bilateral profound sensorineural deafness and demonstrate limited benefit from appropriate binaural hearing aids.4) Children two years of age or older may demonstrate severe to profound hearing loss bilaterally.5) In younger children, limited benefit is defined as lack of progress in the development of simple auditory skills in conjunction with appropriate amplification and participation in intensive aural habilitation over a three to six-month period. It is recommended that limited benefit be quantified on a measure such as the Meaningful Auditory Integration Scale or the Early Speech Perception test.6) In older children, limited benefit is defined as <= 30% correct on the open set Multisyllabic Lexical Neighborhood Test (MLNT) or Lexical Neighborhood Test (LNT), depending upon the childs cognitive and linguistic skills. A three to six-month hearing aid trial is recommended for children without previous aided experience.
Source documents
Other decisions for Cochlear Americas
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260902 · Decided Jul 10, 2026 · 114 days after receipt
Device type: Active Implantable Bone Conduction Hearing System (PFO) · Otolaryngology (ENT)
- Cochlear Osia System510(k)
K240155 · Decided Apr 18, 2024 · 90 days after receipt
Device type: Active Implantable Bone Conduction Hearing System (PFO) · Otolaryngology (ENT)
- Instrument Case510(k)
K231604 · Decided Aug 24, 2023 · 84 days after receipt
Device type: Sterilization Wrap Containers, Trays, Cassettes & Other Accessories (KCT) · Hospital Medicine & Nursing
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.